You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 HOME Hepatitis C Hepatitis B HIV and AIDS HIV-HCV Coinfection HIV-HBV Coinfection About Us
 HIV and Hepatitis.com Coverage of the
5
th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009)
 July 19 - 22, 2009, Cape Town, South Africa
 The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.
Library of Slides and Posters
HIV and AIDS Articles
HIV-HCV and HIV-HBV Coinfection Articles


HIV and AIDS Articles

Therapies for Treatment-Experienced Patients
Genotypic Testing Predicts Response to Maraviroc (Selzentry) as well as Viral Tropism Testing
Once-daily Lopinavir/ritonavir (Kaletra) Works as Well as Twice-daily dosing in Treatment-naive HIV Patients
Once Daily Darunavir/ritonavir: Experience in a Single Centre
FOTO Study Finds 5 Days On, 2 Days Off Treatment Strategy Maintains HIV Suppression while Reducing Cost
First-Line Therapy for Treatment-Naive Patients
Treatment-naive Patients with Confirmed CCR5-tropic HIV Continue to Respond Well to Maraviroc (Selzentry) at 96 Weeks in the MERIT Study
Nevirapine (Viramune) Has Equal Efficacy but a More Favorable Lipid Profile Compared with Boosted Atazanavir (Reyataz)
Once Daily Darunavir/ritonavir: Experience in a Single Centre
 Integrase Inhibitor Raltegravir (Isentress) Compares Favorably to Efavirenz (Sustiva) at 144 Weeks in Treatment-naive Patients
Experimental HIV Therapies
Potent Next-generation Experimental Integrase Inhibitor S/GSK134957 Debuts at IAS 2009
Adverse Events
Lipid and Glucose Changes Related to Boosted Darunavir (Prezista) in Children and Adolescents with HIV: DELPHI Study
HIV Positive People without Viral Hepatitis or Other Risk Factors Have a Fibrosis Distribution Similar to the General Population
Liver Toxicity Related to Raltegravir (Isentress) Is Uncommon among HIV Patients, including those with HIV-HCV Coinfection
Impact of Adverse Events on Survival of African HIV Patients in the DART Trial
Confounding Factors May Explain Elevated Cardiovascular Risk in Patients Taking Abacavir
Intensive Cardiovascular Intervention Lowers Blood Lipids in HIV Patients on Antiretroviral Therapy
HIV Transmission and Prevention
Daily Acyclovir (Zovirax) Delays HIV Disease Progression in People Coinfected with HIV and Herpes Simplex Virus Type 2
Related Conditions
Presence of Human Papillomavirus (HPV) Increases Risk of HIV Infection
HIV Positive People without Viral Hepatitis or Other Risk Factors Have a Fibrosis Distribution Similar to the General Population
Daily Acyclovir (Zovirax) Delays HIV Disease Progression in People Coinfected with HIV and Herpes Simplex Virus Type 2
Longer Duration of HIV Infection and Detectable Viral Load Linked to Higher Risk of Non-AIDS-defining Cancers
Intensive Cardiovascular Intervention Lowers Blood Lipids in HIV Patients on Antiretroviral Therapy
IAS 2009 Opening Session Emphasizes Need for Expanded Treatment of HIV and Tuberculosis in Developing Countries
Research Offers Guidance on Scaling Up HIV and Tuberculosis Treatment Programs in Resource-limited Countries
Widespread Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis Prevalence in South Africa
HIV Latency Is a Myth: New HIV Paradigm May Focus on Inflammation
Developing Countries
Can People in Low-income Countries Benefit from Antiretroviral Therapy without Routine Laboratory Monitoring?
Impact of Adverse Events on Survival of African HIV Patients in the DART Trial
IAS 2009 Opening Session Emphasizes Need for Expanded Treatment of HIV and Tuberculosis in Developing Countries
Research Offers Guidance on Scaling Up HIV and Tuberculosis Treatment Programs in Resource-limited Countries
Widespread Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis Prevalence in South Africa
Women and Children
Large Numbers of Women and People of Color Can Be Successfully Enrolled in HIV Studies in U.S.
Antiretroviral Therapy for Mothers Improves Pregnancy Outcomes and Reduces Risk of HIV Transmission via Breast-feeding

HIV-HCV and HIV-HBV Coinfection Articles
HIV-HCV Coinfected Patients Treated with NRTI-Sparing Antiretroviral Regimens Respond Better to Pegylated Interferon plus Ribavirin
Poor Outcomes with Ribavirin Pre-treatment and Double-dose Pegylated Interferon in HIV-HCV Coinfected Patients
Liver Toxicity Related to Raltegravir (Isentress) Is Uncommon among HIV Patients, including those with HIV-HCV Coinfection
Hepatitis C Treatment and Normal Glucose Metabolism Promote Improved Fibrosis in HIV-HBV Coinfected People
Antiretroviral Regimens with Lamivudine (Epivir) Produce Good CD4 Cell Recovery and HIV Suppression with Fewer Liver Flares in HIV-HBV Coinfected Patients
Liver Fibrosis May Regress in HIV-HCV Coinfected Patients with Sustained Response to Pegylated Interferon plus Ribavirin
 

Library of Slides and Posters

Therapies for Treatment-Experienced Patients
Lopinavir/ritonavir (LPV/r) tablets administered once- (DQ) or twice-daily (BID) with NRTIs in antiretroviral-experienced HIV-1 infected subjects: Results of a 48-week randomized trial (Study M06-802)
R Zajdenverg and others. IAS 2009.
Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials
J Eron and others. IAS 2009.
Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results
A Mills and others. IAS 2009.
Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials
T Campbell and others. IAS 2009.
Recovery of Functional Immunity over 48 Weeks with Darunavir-based Therapy in the GRACE Immunology Substudy
C Tsoukas and others. IAS 2009.
GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women
K Squires and others. IAS 2009.
Integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients Experiencing Virologic Failure while on Raltegravir Therapy
M Underwood and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
First-Line Therapy for Treatment-Naive Patients
Efficacy and Safety of Atazanavir/RTV vs. Lopinavir/RTV in Treatment-Nave Patients with Advanced Disease: CASTLE Study 96-Week Results
J Uy and others. IAS 2009.
Comparable Safety and Efficacy With Once-daily (QD) Versus Twice-daily (BID) Dosing of Lopinavir/ritonavir (LPV/r) Tablets With Emtricitabine (FTC) + Tenofovir DF (TDF) in Antiretroviral (ARV)-nave, HIV-1-infected Subjects: 96-Week Results of the Randomized Trial M05-730
J Gonzalez and others. IAS 2009.
Prospective randomised comparison of Nevirapine and Atazanavir/ritonavir both combined with Tenofovir DF/Emtricitabine in treatment-nave HIV-1 infected patients: ARTEN Study week 48 results
V Soriano and others. IAS 2009.
ARTEMIS:Week 96 safety and efficacy of darunavir/r by gender, age and race
J Fourie and others. IAS 2009.
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-nave, HIV-1-infected ARTEMIS patients at Week 96
E Baraldi and others. IAS 2009.
Differences in Virologic Response Among African-Americans and Females Regardless of Therapy in the HEAT Study
K Smith and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Similar Declines in HIV-1 RNA (Viral load, VL) from Baseline (BL) to 96 Weeks Observed in Subjects Randomized to ABC/3TC or TDF/FTC each with Lopinavir/Ritonavir (LPV/r) in the HEAT Trial (EPZ104057)
L Yau and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Similar Efficacy and Tolerability of Atazanavir Compared to Atazanavir/Ritonavir, each with ABC/3TC after Initial Suppression with ABC/3TC + ATV/r
K Squires and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Experimental HIV Therapies
Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Nave HIV-1-Infected Patients: ING111521 Protocol
J Lalezari and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients
I Song and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor
A Soto and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Pharmacokinetics (PK) and Safety in Healthy Subjects of S/GSK1349572, a Next Generation, Once-Daily HIV Integrase Inhibitor (INI)
S Min and others. IAS 2009. Copyright GlaxoSmithKline. Used with permission, 2009.
Developing Countries
The Development of AntiRetroviral Therapy in Africa (DART) trial
P Mugyenyi and others. IAS 2009.
Special Populations
48 week lipid- and glucose-related safety profile of darunavir/ritonavir in treatment-experienced, paediatric patients in DELPHI
T Meyers and others. IAS 2009.
The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182
F Conradie and others. IAS 2009.
Bioavailability of Efavirenz Capsule Contents (Sprinkles) Mixed with a Small Amount of Food Compared with Intact Capsules in Healthy Adults
S Kaul and others. IAS 2009.
Treatment Strategies
The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline
J Arribas and others. IAS 2009.
The FOTO Sudy- 48 week Results to assess durability of the strategy of taking Efavirenz, Tenofovir and Emtricitabine Five-days-On, Two-days-Off each week in virologically suppressed patients
C Cohen and others. IAS 2009.

IAS 2009 Conference Coverage
5th IA

 

 

 

 

 

 

S Conference Coverage by HIV and Hepatit

om






 Google Custom Search

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HIV and Hepatitis.com is published by HIV and Hepatitis Treatment Advocates, Inc.